Bryan Garnier - Qiagen (QIA) QIAGEN: Rebased for good (?) | BUY | EUR30 vs. EUR32 (+15%)

Report

Bryan Garnier

Hugo Solvet

QIAGEN: Rebased for good (?) | BUY | EUR30 vs. EUR32 (+15%)

QIAGEN - BUY | EUR30 vs. EUR32 (+15%)
Rebased for good (?)

Are QIAGEN shares rebased for good? (FV EUR30 vs EUR32)
Weak China set to recover by YE19
QIAstat-Dx menu and QFT-Plus/LIAISON delayed to H1 2020

01/11/2019 3 EN

Underlying

Qiagen

See profile

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Hugo Solvet

Other Reports on these Companies

Independent Investment Research

Monthly LMI Update Independent Investment Research

Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked. This compares to the total dividends of 5 cents per share in FY20. The Board has confirmed that, in...

August 6, 2021 August 6, 2021 10 EN

Fundamental Research

Feasibility Study Results in December to be a Catalyst for this Junior

EUR 18.57

November 25, 2019 November 25, 2019 14 EN

Bryan Garnier

QIAGEN: QIAGEN could fetch EUR41-44/share in a takeout | BUY | EUR30(-12%)

QIAGEN - BUY | EUR30(-12%) QIAGEN could fetch EUR41-44/share in a takeout QIAGEN worth EUR41-44/share Highly accretive: QIA could bring up to USD260m in synergies Multiple interests could lead to a higher bid

November 19, 2019 November 19, 2019 3 EN

Onward: Model Update

We update our financial model after Onward medical released FY 2023 results last week The rating remains unchanged with a Buy recommendation and EUR 20 PT.

May 3, 2024 May 3, 2024 1 EN

Cedric Rossi

Cedric Rossi

Hugo Boss: Weak China and month of April spoilt the mood

In our view, the sharp negative market reaction was triggered by subdued trends in China and April trends which were slightly below the Q1 top-line performance (+6% FX-n), on top of another tough comparison base (Q2 2023: +20% FX-n). Whilst FY24 outlook was reiterated, management's relatively cauti

May 3, 2024 May 3, 2024 1 EN

Oscar Haffen Lamm

Oscar Haffen Lamm

Egetis reports Q1, on track with US trial

Egetis reported Q1 2024 results with an operating loss of SEK (68.6m) and a cash position of SEK 251.7m. In the pipeline, the most important update has been to the status of the critical US phase 3 trial, where the company reported that 13/16 patients have been recruited, whereof 6 patients have co

May 3, 2024 May 3, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

QIAGEN: Rebased for good (?) | BUY | EUR30 vs. EUR32 (+15%)

Monthly LMI Update Independent Investment Research

Feasibility Study Results in December to be a Catalyst for this Junior

QIAGEN: QIAGEN could fetch EUR41-44/share in a takeout | BUY | EUR30(-12%)

Onward: Model Update

Hugo Boss: Weak China and month of April spoilt the mood

Egetis reports Q1, on track with US trial

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe